These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

126 related articles for article (PubMed ID: 2189592)

  • 1. High-dose carboplatin, cyclophosphamide, and BCNU with autologous bone marrow support: excessive hepatic toxicity.
    Jones RB; Shpall EJ; Ross M; Coniglio D; Affronti ML; Peters WP
    Cancer Chemother Pharmacol; 1990; 26(2):155-6. PubMed ID: 2189592
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Randomized trial of high-dose chemotherapy with autologous bone marrow support as adjuvant therapy for high-risk, multi-node-positive malignant melanoma.
    Meisenberg BR; Ross M; Vredenburgh JJ; Jones R; Shpall EJ; Seigler HF; Coniglio DM; Wu K; Peters WP
    J Natl Cancer Inst; 1993 Jul; 85(13):1080-5. PubMed ID: 8515495
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Intensive 1,3-bis(2-chloroethyl)-1-nitrosourea (BCNU), NSC #4366650 and cryopreserved autologous marrow transplantation for refractory cancer. A phase I-II study.
    Phillips GL; Fay JW; Herzig GP; Herzig RH; Weiner RS; Wolff SN; Lazarus HM; Karanes C; Ross WE; Kramer BS
    Cancer; 1983 Nov; 52(10):1792-802. PubMed ID: 6354414
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A phase I-II study of cyclophosphamide, thiotepa, and carboplatin with autologous bone marrow transplantation in solid tumor patients.
    Eder JP; Elias A; Shea TC; Schryber SM; Teicher BA; Hunt M; Burke J; Siegel R; Schnipper LE; Frei E
    J Clin Oncol; 1990 Jul; 8(7):1239-45. PubMed ID: 2162912
    [TBL] [Abstract][Full Text] [Related]  

  • 5. High-dose thiotepa alone and in combination regimens with bone marrow support.
    Antman K; Eder JP; Elias A; Ayash L; Shea TC; Weissman L; Critchlow J; Schryber SM; Begg C; Teicher BA
    Semin Oncol; 1990 Feb; 17(1 Suppl 3):33-8. PubMed ID: 2106166
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pulmonary toxicity following carmustine-based preparative regimens and autologous peripheral blood progenitor cell transplantation in hematological malignancies.
    Alessandrino EP; Bernasconi P; Colombo A; Caldera D; Martinelli G; Vitulo P; Malcovati L; Nascimbene C; Varettoni M; Volpini E; Klersy C; Bernasconi C
    Bone Marrow Transplant; 2000 Feb; 25(3):309-13. PubMed ID: 10673703
    [TBL] [Abstract][Full Text] [Related]  

  • 7. High-dose carboplatin, etoposide and cyclophosphamide with autologous bone marrow transplantation for the treatment of advanced malignancies: a phase I study.
    Saez RA; Slease RB; Strnad C; Selby GB; Confer DL; Epstein RB
    Bone Marrow Transplant; 1995 Oct; 16(4):507-14. PubMed ID: 8528165
    [TBL] [Abstract][Full Text] [Related]  

  • 8. High-dose combination alkylating agent preparative regimen with autologous bone marrow support: the Dana-Farber Cancer Institute/Beth Israel Hospital experience.
    Antman K; Eder JP; Elias A; Shea T; Peters WP; Andersen J; Schryber S; Henner WD; Finberg R; Wilmore D
    Cancer Treat Rep; 1987 Feb; 71(2):119-25. PubMed ID: 3542208
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cutaneous toxicity of autologous bone marrow transplantation in nonseminomatous germ cell tumors.
    Linassier C; Colombat P; Reisenleiter M; Haillot O; Chazard M; Binet C; Desbois I; Lamagnere JP
    Cancer; 1990 Mar; 65(5):1143-5. PubMed ID: 2154321
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A phase I study of high-dose ifosfamide and escalating doses of carboplatin with autologous bone marrow support.
    Elias AD; Ayash LJ; Eder JP; Wheeler C; Deary J; Weissman L; Schryber S; Hunt M; Critchlow J; Schnipper L
    J Clin Oncol; 1991 Feb; 9(2):320-7. PubMed ID: 1846407
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Phase I trial with pharmacokinetic analyses of high-dose carboplatin, etoposide, and cyclophosphamide with autologous bone marrow transplantation in patients with refractory germ cell tumors.
    Motzer RJ; Gulati SC; Tong WP; Menendez-Botet C; Lyn P; Mazumdar M; Vlamis V; Lin S; Bosl GJ
    Cancer Res; 1993 Aug; 53(16):3730-5. PubMed ID: 8393380
    [TBL] [Abstract][Full Text] [Related]  

  • 12. High-dose combination alkylating agents with autologous bone marrow support: a Phase 1 trial.
    Peters WP; Eder JP; Henner WD; Schryber S; Wilmore D; Finberg R; Schoenfeld D; Bast R; Gargone B; Antman K
    J Clin Oncol; 1986 May; 4(5):646-54. PubMed ID: 3517240
    [TBL] [Abstract][Full Text] [Related]  

  • 13. High-dose cyclophosphamide, thiotepa, and carboplatin with autologous marrow support in women with measurable advanced breast cancer responding to standard-dose therapy: analysis by age.
    Antman K; Ayash L; Elias A; Wheeler C; Schwartz G; Mazanet R; Tepler I; Schnipper LE; Frei E
    J Natl Cancer Inst Monogr; 1994; (16):91-4. PubMed ID: 7528031
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cyclophosphamide, carmustine, and etoposide with autologous bone marrow transplantation in refractory Hodgkin's disease and non-Hodgkin's lymphoma: a dose-finding study.
    Wheeler C; Antin JH; Churchill WH; Come SE; Smith BR; Bubley GJ; Rosenthal DS; Rappaport JM; Ault KA; Schnipper LE
    J Clin Oncol; 1990 Apr; 8(4):648-56. PubMed ID: 2313334
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A single center experience with bone marrow transplantation for high risk neuroblastoma.
    Ladenstein R; Lasset C; Bouffet E; Brunat-Mentigny M; Biron P; Philip I; Chauvin F; Philip T
    Bone Marrow Transplant; 1991; 7 Suppl 2():93. PubMed ID: 1878741
    [No Abstract]   [Full Text] [Related]  

  • 16. A phase II study of high-dose cyclophosphamide, thiotepa, and carboplatin with autologous marrow support in women with measurable advanced breast cancer responding to standard-dose therapy.
    Antman K; Ayash L; Elias A; Wheeler C; Hunt M; Eder JP; Teicher BA; Critchlow J; Bibbo J; Schnipper LE
    J Clin Oncol; 1992 Jan; 10(1):102-10. PubMed ID: 1727912
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Intensive chemotherapy with cyclophosphamide, carmustine, and etoposide followed by autologous bone marrow transplantation for relapsed Hodgkin's disease.
    Reece DE; Barnett MJ; Connors JM; Fairey RN; Fay JW; Greer JP; Herzig GP; Herzig RH; Klingemann HG; LeMaistre CF
    J Clin Oncol; 1991 Oct; 9(10):1871-9. PubMed ID: 1919637
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Dose-intensive chemotherapy in refractory germ cell cancer--a phase I/II trial of high-dose carboplatin and etoposide with autologous bone marrow transplantation.
    Nichols CR; Tricot G; Williams SD; van Besien K; Loehrer PJ; Roth BJ; Akard L; Hoffman R; Goulet R; Wolff SN
    J Clin Oncol; 1989 Jul; 7(7):932-9. PubMed ID: 2544687
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Chemo-/immunotherapy in advanced malignant melanoma: carboplatin and DTIC or cisplatin, dtic, bcnu and tamoxifen followed by immunotherapy with interleukin 2 and interferon alpha-2a].
    Kirchner HH; Atzpodien J; Poliwoda H
    Med Klin (Munich); 1996 Apr; 91 Suppl 3():44-9. PubMed ID: 8692119
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Intensive chemotherapy with autologous bone marrow transplantation for small-cell lung cancer.
    Souhami RL; Hajichristou HT; Miles DW; Earl HM; Harper PG; Ash CM; Goldstone AH; Spiro SG; Geddes DM; Tobias JS
    Cancer Chemother Pharmacol; 1989; 24(5):321-5. PubMed ID: 2547528
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.